GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » 3-Year Dividend Growth Rate

Novelion Therapeutics (STU:QLTA) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2019)


View and export this data going back to . Start your Free Trial

What is Novelion Therapeutics 3-Year Dividend Growth Rate?

Novelion Therapeutics's Dividends per Share for the three months ended in Mar. 2019 was €0.00.

The historical rank and industry rank for Novelion Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

STU:QLTA's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Novelion Therapeutics's Dividend Payout Ratio for the three months ended in Mar. 2019 was 0.00. As of today, Novelion Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Novelion Therapeutics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Novelion Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novelion Therapeutics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Novelion Therapeutics's 3-Year Dividend Growth Rate falls into.


Novelion Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Novelion Therapeutics  (STU:QLTA) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Novelion Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2019 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2019 )/ EPS without NRI (Q: Mar. 2019 )
=0/ 0
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelion Therapeutics 3-Year Dividend Growth Rate Related Terms>

Novelion Therapeutics (STU:QLTA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » 3-Year Dividend Growth Rate
Comparable Companies
DFFN TSXV:KLY TSXV:QPT ASX:PTX ROCO:4197 XSAT:WNT PTIX IST:RTALB TROV NOVN MATN LSE:TRX ASX:NYR ATOS TSXV:BCT JAGX TSX:CTX ROCO:6744 ACHV EMBI
Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Website
http://www.novelion.com
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.